New cancer therapy takes personalized medicine to a new level

If a patient does not respond to personalized cancer therapies, their remaining hope is for a clinical trial that would offer access to medicines yet to be approved, treatments whose safety and effectiveness are unknown. Yet hospitals also often offer treatments that were once successful for others whose cancer cells are genetically similar. Wu is now optimistic about a third option - using an artificial intelligence system she helped develop that can predict how cancer medications waffect patients based on data from genetic patterns in their tumor tissues.ill

The features of cancer clinicians and dependence on generations-old tools to make decisions have raised the appeal of alternative strategies, including the use of AI predictors that could populate drug trials more efficiently with patients more likely to benefit from experimental drugs. Patients paired with algorithms have experienced significant gains - hospital mortality rates fell dramatically by 25 percent, indicating greater success rates in fighting off tumors while they're still small and fewer side effects among patients who take the medications.

The article is talking about new forms of Cancer treatment

—

The specificity of treatment based on genetics is not just some futuristic idea anymore. Aston University in Birmingham, England has now revealed their cancer therapy that targets tumors and leaves others healthy. This therapy uses artificial intelligence to understand tumors and their characteristics to identify individualized treatments for them.

This new system, called the Excelllence Program, enables the use of machine learning in personalized healthcare to make customized treatments available for patients that were not meant to be treated before due to being unclassifiable. This system was trained by comparing its observations with tissues from surgical samples using machine learning techniques through a neural network algorithm. The AI's analysis is done on paths two or three times as fast than current systems while twice as accurately. The results will be ready within weeks after completion of this data-set making it accessible to healthcare systems everywhere at a low cost and collaborative manner which will improve the cancer care world over with more devices getting updated every day and surgeries possible with less

—

Clinical trials are only available for a small percentage of cancer patients. Therefore, new treatments are not yet available for 10 out of 10 patients. Genomic sequencing has been changing this pattern on a widespread level and will change in the future as well.

Doctors now already look at

—

The Eastern Cooperative Oncology Group (ECOG) trial, led by Dr. Victor Gordeuk at the University of North Georgia’s Cancer Center in Atlanta, offers new hope for personalized medicine in cancer treatment.

The study is enrolling 25 children and young adults with advanced neuroblastoma cancer or brain tumors and will measure the effects of withholding standard treatment as well as a six-month course of radiation therapy following surgery.

This way they can answer key questions - will going off-protocol improve patient outcomes? And can benefits be maintained with lower doses of steroids following surgery?

There are high hopes that this study could pave the way to a new form of personalized medicine that could improve outcomes for many more children suffering from life-threatening cancers and brain tumors.

—

This recent study looks at the use of chemotherapy in 2 different scenarios with 2 different techniques to measure cells that indicate cancer.

Enhancing Chemotherapy Therapy with Omics Technology, i.e., precision medicine, thereby reducing the risk of malignant cells progression and relapse:

Chemotherapy is a form of medicine for cancer; it eliminates all defective cells that multiply in the body quickly by damaging their genetic makeup at cellular level. It’s an effective treatment in some cases, as well as a way to slow down its progress on other occasions.” Performance metrics for chemotherapies are complex and hard to quantify by any "universal" approach from both an individual response time-course basis and large sample to small sample basis because both factors vary drastically for patients [1]. The authors wanted to look at this treatment with omics technology that would provide more precise instructions in terms of efficacy vs safety mechanisms which could help clinicians know what therapeutic strategy should be used best for each

—

Introducing mesothelioma treatment with liquid biopsy. For the first time, physicians can obtain a sample of cancer cells that escapes the body within 13 minutes and determine in live, or soon after biopsy, whether (and which) specific molecular mutations are present.

Liquid biopies were initially limited to testing for mutations in just two genes and were of relevance mostly as follow-up tests for patients with tumors in tissues amenable to surgery. But researchers in recent years have invented minimally-invasive techniques that can enable sample procurement from almost any part of the body, precisely when it is needed. Many such diseases from melanoma to pancreatic cancer show characteristic genetic features that can be detected through a urine or blood sample.